| Literature DB >> 35187522 |
Karen Y Oróstica1, Sebastian Contreras2, Anamaria Sanchez-Daza3, Jorge Fernandez1, Viola Priesemann2, Álvaro Olivera-Nappa3.
Abstract
Entities:
Year: 2022 PMID: 35187522 PMCID: PMC8837806 DOI: 10.1016/j.lana.2022.100203
Source DB: PubMed Journal: Lancet Reg Health Am ISSN: 2667-193X
Figure 1SARS-CoV-2 genomic surveillance in Chile. (a) Surveillance at Points of Entry (POEs) has provided an early alert for the onset of community transmission of introduced variants. For example, the Lambda, Gamma, Mu, and Delta variants were markedly present in the samples collected at POEs at a given time and shortly after had a substantial contribution to community transmission (b). (c) As of 9 Jan 2022, 86.6% of the Chilean population is fully vaccinated and 60.5% has received a booster jab. Despite the high vaccine coverage, the booster scheme is typically heterologous; 55.3% of the administered vaccines are inactivated virus vaccines (Sinovac's CoronaVac) and 36.4% mRNA-based (Pfizer-BioNTech's BNT162b2). Early reports suggest that vaccine-elicited neutralisation against Omicron might be lower in these settings. (d) Scheme: In the absence of genomic surveillance, declining trends on a previously dominant variant can mask the early stages of the exponential spread of another with increased transmissibility. In such a situation, policymakers would notice the replacement only after the tipping point in case numbers, which is typically too late to prevent a major surge.